358 related articles for article (PubMed ID: 23955273)
21. Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing.
Kristensen LS; Treppendahl MB; Asmar F; Girkov MS; Nielsen HM; Kjeldsen TE; Ralfkiaer E; Hansen LL; Grønbæk K
Sci Rep; 2013 Sep; 3():2789. PubMed ID: 24071855
[TBL] [Abstract][Full Text] [Related]
22. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
[TBL] [Abstract][Full Text] [Related]
23. Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease.
Krajnović M; Jovanović MP; Mihaljević B; Anđelić B; Tarabar O; Knežević-Ušaj S; Krtolica K
Clin Transl Sci; 2014 Oct; 7(5):384-90. PubMed ID: 24815848
[TBL] [Abstract][Full Text] [Related]
24. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
[TBL] [Abstract][Full Text] [Related]
25. Targeting DNA methylation.
Issa JP; Kantarjian HM
Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
[TBL] [Abstract][Full Text] [Related]
26. MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma.
Zhou W; Xu Y; Zhang J; Zhang P; Yao Z; Yan Z; Wang H; Chu J; Yao S; Zhao S; Yang S; Guo Y; Miao J; Liu K; Chan WC; Xia Q; Liu Y
Leukemia; 2022 Jul; 36(7):1861-1869. PubMed ID: 35488020
[TBL] [Abstract][Full Text] [Related]
27. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).
Isshiki Y; Melnick A
Curr Cancer Drug Targets; 2021; 21(4):274-282. PubMed ID: 33413063
[TBL] [Abstract][Full Text] [Related]
29. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
[TBL] [Abstract][Full Text] [Related]
30. Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.
Facciotto C; Casado J; Turunen L; Leivonen SK; Tumiati M; Rantanen V; Kauppi L; Lehtonen R; Leppä S; Wennerberg K; Hautaniemi S
Clin Epigenetics; 2019 Dec; 11(1):192. PubMed ID: 31829282
[TBL] [Abstract][Full Text] [Related]
31. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
Song YH; Zhong MZ; Gan PP; Yi PY; Tang YH; Liu YP; Jiang JQ; Li L
Tumour Biol; 2014 Dec; 35(12):11809-17. PubMed ID: 25344211
[TBL] [Abstract][Full Text] [Related]
32. Arsenic disulfide promoted the demethylation of
Chen C; Wang L; Liu Y; Du S; Teng Q
PeerJ; 2024; 12():e17363. PubMed ID: 38766487
[TBL] [Abstract][Full Text] [Related]
33. Targeted inhibition of genome-wide DNA methylation analysis in epigenetically modulated phenotypes in lung cancer.
Dai SP; Xie C; Ding N; Zhang YJ; Han L; Han YW
Med Oncol; 2015 Jun; 32(6):615. PubMed ID: 25926333
[TBL] [Abstract][Full Text] [Related]
34. [Demethylating medication in myelodysplastic syndrome].
Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH
Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034
[TBL] [Abstract][Full Text] [Related]
35. Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway.
Zhou Z; Ma D; Li P; Wang P; Liu P; Wei D; Wang J; Qin Z; Fang Q; Wang J
Aging (Albany NY); 2020 Jun; 12(12):11364-11385. PubMed ID: 32570218
[TBL] [Abstract][Full Text] [Related]
36. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
37. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Mozos A; Roué G; López-Guillermo A; Jares P; Campo E; Colomer D; Martinez A
Am J Pathol; 2011 Nov; 179(5):2601-10. PubMed ID: 21907693
[TBL] [Abstract][Full Text] [Related]
38. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.
Brem EA; Li H; Beaven AW; Caimi PF; Cerchietti L; Alizadeh AA; Olin R; Henry NL; Dillon H; Little RF; Laubach C; LeBlanc M; Friedberg JW; Smith SM
J Geriatr Oncol; 2022 Mar; 13(2):258-264. PubMed ID: 34686472
[TBL] [Abstract][Full Text] [Related]
39. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
[TBL] [Abstract][Full Text] [Related]
40. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
